We have previously shown that antigen-induced eosinophil recruitment into the tissue of sensitized mice is mediated by CD4 ⍣ T cells and IL-5. To determine whether the induction of oral tolerance down-regulates antigen-induced eosinophil recruitment into the tissue, we studied the effect of oral administration of a protein antigen on antigen-induced eosinophil infiltration in the trachea of sensitized mice, on antigen-induced CD4 ⍣ T cell infiltration and IL
Introduction
Allergic inflammation is characterized by a prominent eosinophil infiltrate. In addition to the infiltration of eosinophils, it has been shown that there is an increase in CD4 ϩ T cells and IL-5-producing cells at the sites of allergic late-phase reaction (1) (2) (3) , suggesting that CD4 ϩ T cells and their cytokine IL-5 might be involved in antigen-induced eosinophil recruitment into the tissue. Furthermore, in a murine model of airway latephase reaction we have recently provided direct evidence that CD4 ϩ T cells and IL-5 mediate antigen-induced eosinophil recruitment into the tissue of sensitized mice (4) . Thus, the manipulation for inducing selective inactivation of antigenspecific T h 2 cells (5) is a rational approach to the control of allergic inflammation.
Oral administration of antigen induces antigen-specific peripheral T cell tolerance (6, 7) . Recent studies have shown Correspondence to: I. Iwamoto Transmitting editor: T. Sasazuki Received 11 August 1997, accepted 15 December 1997 that oral tolerance is mediated by at least two mechanisms, active suppression (8) (9) (10) and clonal anergy of T h 1 cells (11) (12) (13) , which are determined mainly by antigen dosage (9, 14) . Low-dose feeding of antigens induces active suppression mediated by regulatory T cells and the suppression is adoptively transferred in vivo. The regulatory cells inhibit cellular immune responses in vivo and in vitro by the release of immunosuppressive cytokines such as transforming growth factor (TGF)-β associated with enhanced T h 2 cell cytokine IL-4 production (8) (9) (10) . In contrast, it has been shown that highdose feeding of antigens induces clonal anergy of T h 1 cells (11) (12) (13) and that the tolerance is not transferable in vivo. Thus, IL-2 and IFN-γ production in vitro is decreased (11, 12) and IL-4 production is not affected (13) . Furthermore, it has been shown that the induction of oral tolerance suppresses T h 1 cell-mediated autoimmune diseases in animals and humans (7) . However, there has been as yet no direct evidence that the induction of oral tolerance prevents antigeninduced eosinophil recruitment into the tissue. Therefore, we decided to determine whether the induction of oral tolerance down-regulates antigen-induced eosinophil recruitment into the tissue and, if so, what the mechanism is. For these purposes, we examined the effect of oral administration of a protein antigen in high doses on antigeninduced eosinophil infiltration in the trachea of sensitized mice, on antigen-induced CD4 ϩ T cell infiltration and IL-5 production in the airways, and on the in vitro production of IL-2, IL-4, IL-5 and IFN-γ in spleen cells of the mice. Our results indicate that high-dose oral tolerance induces not only T h 1 but also T h 2 cell tolerance in vivo and thereby inhibits antigen-induced eosinophil recruitment into the tissue.
Methods

Mice
Female BALB/c mice (8 weeks old) were purchased from Charles River Japan (Atsugi, Japan). In some experiments, DO11.10 TCR transgenic mice (BALB/c background), which have a TCRαβ that recognizes chicken ovalbumin (OVA) in the context of I-A d (15) , were used.
Induction of oral tolerance and immunization
Mice were fed 25 mg of OVA or BSA (Sigma, St Louis, MO) dissolved in 0.3 ml of PBS (pH 7.2) or PBS alone 3 times every 24 h by gastric intubation with an 18-gauge stainless steel animal feeding needle. Two weeks after the final antigen feeding, the mice were immunized i.p. once with 1 µg of OVA in 4 mg of aluminum hydroxide.
Antigen-induced eosinophil infiltration in mouse trachea
The eosinophil infiltration into the trachea was induced by the inhalation of antigen in sensitized mice and the number of eosinophils infiltrating into the submucosal tissue of trachea was evaluated as described previously (4) . Briefly, 12 days after the immunization, the sensitized mice were inhaled with aerosolized OVA (50 mg/ml) dissolved in 0.9% saline by a DeVilbiss 646 nebulizer (DeVilbiss, Somerset, PA) for 20 min. As a control, 0.9% saline alone was administered by the nebulizer. At various intervals after the inhalation, the mice were killed by cervical dislocation and the tracheas were excised. After the tracheas were fixed in 10% formalin, the specimens were embedded in paraffin, sectioned to 3 µm thick, and stained with Luna solution and hematoxylin & eosin solution. The number of eosinophils in the submucosal tissue of trachea was counted in Luna-stained sections and expressed as the number of eosinophils per the length of the basement membrane of trachea, which was measured with a digital curvimeter. The eosinophil infiltration into the trachea of sensitized mice began at 6 h after antigen inhalation and reached a peak at 24 h (4).
Antigen-induced CD4 ϩ T cell infiltration in the trachea CD4 ϩ T cell infiltration into the trachea was assessed by direct staining with streptoavidin-biotinylated antibody technique as described previously (16) . Briefly, trachea was removed and frozen with OCT compound (Miles Laboratories, Naperville, IL) in a liquid nitrogen bath. After acetone-fixed cryostat sections (3 µm thick) were treated with normal rabbit serum, the sections were incubated with biotinylated anti-L3T4 mAb (Becton Dickinson, Mountain View, CA) at room temperature for 2 h. As a negative control, biotinylated normal rat IgG was used. Sections were then incubated with the streptoavidin conjugated with horseradish peroxidase (Vector, Burlingame, CA) at room temperature for 30 min, followed by the reaction with 3Ј,3-diaminobenzidine in Tris-HCl buffer containing H 2 O 2 for 5 min. The immunostained cells were counted and expressed as described above. CD4 ϩ T cell infiltration into the trachea occurred 2 h after antigen inhalation and reach a peak at 12-24 h (16).
IL-5 levels in bronchoalveolar lavage fluids
Bronchoalveolar lavage was performed with 1.2 ml of PBS at 24 h after saline or OVA inhalation in control and OVA-fed mice. The lavage fluid was centrifuged at 400 g for 10 min at 4°C and the amount of IL-5 in the supernatant was measured by the enzyme immunoassays as described below.
In vitro production of cytokines in spleen cells
The spleen was removed from the mice 12 days after the immunization with OVA, and a single-cell suspension of spleen cells was prepared and washed twice in RPMI 1640 medium with 1% FCS. Cells (1ϫ10 6 ) were then suspended in 200 µl of RPMI 1640 medium supplemented with 10% FCS, 10 mM glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin and 0.05 mM 2-mercaptoethanol, and were cultured in triplicate in the absence or presence of OVA (1, 10, 100 and 500 µg/ ml) in a 96-well microtiter plate at 37°C for 24 or 48 h in humidified 5% CO 2 and 95% air. After the culture, the culture supernatant was collected at 24 h for IL-2 production and at 48 h for IL-4, IL-5 and IFN-γ production, and was centrifuged at 400 g at 4°C. The cell-free supernatants were stored at -80°C until use for cytokine assay. As for TGF-β production, spleen cells were suspended in 200 µl of serum-free AIM-V medium (Gibco, Grand Island, NY) supplemented with 2 mM glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin, and were cultured for 96 h with or without 100 µg/ml of OVA. Prior to the measurement of TGF-β, the samples were activated by acidification with HCl and neutralized to pH 7.2-7.4 with NaOH.
The amount of IL-2, IL-4, IL-5, IL-10, IFN-γ and TGF-β in the culture supernatant of spleen cells was determined by solid-phase sandwich enzyme immunoassays using murine IL-2, IL-4, IL-5, IL-10 and IFN-γ ELISA kits (Endogen, Boston, MA) and a TGF-β ELISA kit (Genzyme, Cambridge, MA). The assay was performed in duplicate according to the manufacturers' recommendations. The minimum significant values of these assays were 5 pg/ml of IL-2, IL-4 and IL-5, 0.14 U/ml of IL-10, 15 pg/ml of IFN-γ, and 50 pg/ml of TGF-β respectively.
Effect of anti-TGF-β antibody
To determine whether the inhibition of antigen-induced eosinophil recruitment into the mouse trachea induced by oral administration of antigen is mediated by TGF-β production, we examined the effect of anti-TGF-β antibody on antigeninduced eosinophil infiltration in the trachea of sensitized mice. Chicken anti-TGF-β neutralizing antibody (300 µg/day) (R & D Systems, Minneapolis, MN) was injected i.p. into OVAfed mice for 5 days from 2 days prior to until 2 days after the immunization with OVA in aluminum hydroxide. Mice were then challenged with inhaled OVA 12 days after the immunization and the eosinophil infiltration into the trachea was evaluated at 24 h after OVA inhalation.
Flow cytometry
Spleen cells (1ϫ10 6 ) suspended in PBS containing 0.1% NaN 3 and 1% FCS were incubated on ice with a mixture of FITC-labeled anti-CD4 mAb (Caltag, San Francisco, CA) and biotinylated KJ1-26 mAb (17) , and then with phycoerythrinlabeled streptoavidin (Gibco). After washing with PBS containing 0.1% NaN 3 and 1% FCS, the intensity of the fluorescence of cells was calibrated by FACScan (Becton Dickinson).
Determination of IgE antibody in serum
The titer of antigen-specific IgE antibody in mouse sera was assessed by a 24-h passive cutaneous anaphylaxis (PCA) reaction as described by Ovary (18) using male SpragueDawley rats.
Data analysis
Data are summarized as mean Ϯ SD. The statistical analysis of the results was performed by the analysis of variance using Fisher's least significant difference test for multiple comparisons. P Ͻ 0.05 was considered significant.
Results
Oral administration of antigen inhibits antigen-induced eosinophil infiltration into the mouse trachea
Oral administration of antigen in high doses prevented antigen-induced eosinophil recruitment into the mouse trachea. Oral administration of OVA (25 mg, 3 times every 24 h) 2 weeks before the immunization with OVA significantly decreased OVA-induced eosinophil infiltration into the trachea of OVA-sensitized mice at 24 h after OVA inhalation by 89% (PBS-fed 6.28 Ϯ 0.87 versus OVA-fed 0.66 Ϯ 0.49 eosinophils/ mm, mean Ϯ SD, n ϭ 6 mice in each group, P Ͻ 0.001) (Fig. 1) . In contrast, oral administration of BSA (25 mg, 3 times every 24 h) had no significant effect on OVA-induced eosinophil infiltration in the trachea of OVA-sensitized mice at 24 h (n ϭ 6) (Fig. 1) .
In addition, the inhibition of antigen-induced eosinophil infiltration in the mouse trachea by oral administration of OVA was observed during the entire course of airway eosinophilia (i.e. at 9, 24 and 48 h after OVA inhalation, n ϭ 6) (Fig. 2) .
Oral administration of antigen decreases antigen-induced CD4 ϩ T cell infiltration into the trachea Because it has been shown that antigen-induced eosinophil recruitment into the tissue of sensitized mice is mediated by CD4 ϩ T cells and IL-5 (4), we also studied the effect of oral administration of antigen on antigen-induced CD4 ϩ T cell infiltration in the trachea. Oral administration of OVA for Fig. 1 . Effect of oral administration of antigen on antigen-induced eosinophil infiltration in mouse trachea. BALB/c mice were fed 25 mg of OVA (or BSA) 3 times every 24 h. As a control, mice were fed PBS alone. Two weeks after the final antigen feeding, the mice were immunized i.p. with OVA. Mice were then challenged with inhaled OVA 12 days after the immunization and the number of eosinophils infiltrating into the submucosal tissue of trachea was counted at 24 h after antigen inhalation. Data are means Ϯ SD for six mice in each group. *Significantly different from the mean value of the control response (PBS-fed), P Ͻ 0.001. Fig. 2 . Time course of the inhibition of antigen-induced eosinophil infiltration in mouse trachea by oral administration of antigen. Mice were fed OVA (circles) or PBS (squares), immunized with OVA and challenged with inhaled OVA as described in Fig. 1 . The eosinophil infiltration in the trachea was then examined at 9, 24 and 48 h after OVA inhalation. Data are means Ϯ SD for six mice in each group. *Significantly different from the mean value of the corresponding control response (PBS-fed), P Ͻ 0.001.
3 days significantly decreased OVA-induced CD4 ϩ T cell infiltration into the trachea of OVA-sensitized mice at 24 h after OVA inhalation by 91% (PBS-fed 0.88 Ϯ 0.25 versus OVA-fed 0.08 Ϯ 0.04 CD4 ϩ T cells/mm, n ϭ 6 mice in each group, P Ͻ 0.001) (Fig. 3) . In contrast, oral administration of BSA for 3 days had no significant effect on OVA-induced CD4 ϩ T cell infiltration in the trachea of OVA-sensitized mice at 24 h (n ϭ 6) (Fig. 3) .
We further examined the effect of oral administration of antigen on IL-5 levels in the bronchoalveolar lavage fluids (BALF) of sensitized mice. IL-5 levels in BALF of control (PBSfed) mice were significantly increased at 24 h after OVA inhalation (178.9 Ϯ 32.6 pg/ml, n ϭ 5 mice, P Ͻ 0.001) as Fig. 3 . Effect of oral administration of antigen on antigen-induced CD4 ϩ T cell infiltration in mouse trachea. Mice were fed OVA, BSA or PBS, immunized with OVA and challenged with inhaled OVA as described in Fig. 1 . CD4 ϩ T cell infiltration in the trachea was then examined at 24 h after OVA inhalation. The number of CD4 ϩ T cells infiltrating in the trachea of OVA-sensitized mice at 24 h after saline inhalation was less than 0.03/mm. Data are means Ϯ SD for six mice in each group. *Significantly different from the mean value of the control response (PBS-fed), P Ͻ 0.001. Fig. 4 . Effect of oral administration of antigen on antigen-specific IgE production in mice. Mice were fed OVA (or BSA) and immunized with OVA as described in Fig. 1 . Twelve days after the immunization, anti-OVA IgE antibody in sera was determined by PCA reaction. Data are means Ϯ SD for six mice in each group. *Significantly different from the mean value of the control response (PBS-fed), P Ͻ 0.001. compared with those of saline inhalation (21.3 Ϯ 2.7 pg/ml, n ϭ 5). IL-5 levels in BALF after OVA inhalation were significantly decreased in OVA-fed mice by 86% (26.3 Ϯ 4.7 pg/ml, n ϭ 5) as compared with those of control mice.
Oral administration of antigen inhibits antigen-specific IgE production
Oral administration of antigen also prevented antigen-specific IgE production in mice. Oral administration of OVA for 3 days significantly decreased anti-OVA IgE antibody in sera of OVAsensitized mice at 12 days after the immunization with OVA by 97% (PBS-fed 254 Ϯ 14 versus OVA-fed 8 Ϯ 8 PCA titers, n ϭ 6 mice in each group, P Ͻ 0.001) (Fig. 4) . However, oral administration of BSA for 3 days had no significant effect on anti-OVA IgE antibody in sera of OVA-sensitized mice (n ϭ 6) (Fig. 4) .
Oral administration of antigen inhibits antigen-induced T h 1 and T h 2 cell cytokine production
Oral administration of antigen induced antigen-specific T h 1 and T h 2 cell tolerance in mice. In vitro OVA-induced IL-2 production was significantly decreased in spleen cells of OVA-fed mice by 81-87% as compared with that of control mice (n ϭ 5 mice in each group, P Ͻ 0.005) (Fig. 5) . In vitro OVA-induced IFN-γ production was also significantly decreased in spleen cells of OVA-fed mice by 76-87% (n ϭ 5, P Ͻ 0.005) (Fig. 5) . OVA-induced T cell proliferation in vitro was also significantly decreased by oral administration of OVA by 87% (data not shown).
Furthermore, in vitro OVA-induced IL-4 and IL-5 production was also significantly decreased in OVA-fed mice by 72-93 and 92-97% respectively as compared with that of control mice (n ϭ 5, P Ͻ 0.005) (Fig. 6 ). In vitro OVA (100 µg/ml)-induced IL-10 production was also significantly reduced in OVA-fed mice by 71% (PBS-fed 1.24 Ϯ 0.19 versus OVA-fed 0.36 Ϯ 0.05 U/ml, n ϭ 3, P Ͻ 0.01).
Effect of anti-TGF-β antibody
Pretreatment with anti-TGF-β antibody at the time of immunization with antigen had no significant effect on the inhibition of antigen-induced eosinophil recruitment into the trachea of antigen-fed mice. The i.p. preinjection with anti-TGF-β antibody (300 µg) for 5 days from 2 days prior to until 2 days after the immunization with OVA did not significantly affect OVA-induced eosinophil infiltration into the trachea of OVAfed mice at 24 h after OVA inhalation (n ϭ 5 mice in each group) (Fig. 7) . The preinjection with anti-TGF-β antibody had no significant effect on anti-OVA IgE antibody in sera of OVAfed mice at 12 days after the immunization with OVA either (n ϭ 5) (Fig. 7) .
In addition, in vitro OVA-induced production of active TGF-β was not significantly observed in spleen cells of either control mice or OVA-fed mice (Ͻ50 pg/ml, n ϭ 5). Fig. 7 . Effect of anti-TGF-β antibody on antigen-induced eosinophil infiltration in the trachea and antigen-specific IgE production in mice. Mice were fed OVA or PBS and immunized with OVA as described in Fig. 1 . Anti-TGF-β neutralizing antibody (300 µg/day) was injected i.p. into the mice for 5 days from 2 days prior to until 2 days after the immunization with OVA. Twelve days after the immunization, antigeninduced eosinophil infiltration in the trachea at 24 h after OVA inhalation and anti-OVA IgE antibody in sera were evaluated as described above. Data are means Ϯ SD for five mice in each group.
Oral administration of antigen does not induce deletion of antigen-specific T cells in vivo CD4 ϩ KJ1-26 ϩ splenic T cells were not deleted in DO11.10 TCR transgenic BALB/c mice 2 weeks after OVA feeding (25 mg) for 3 days by FACS analysis (PBS-fed 46.8% versus OVAfed 49.9% of CD4 ϩ KJ1-26 ϩ cells/total CD4 ϩ cells) (Fig. 8) . Furthermore, no deletion of CD4 ϩ KJ1-26 ϩ splenic T cells was observed at any time points until 26 days after OVA feeding (data not shown). In addition, oral administration of OVA for 3 days similarly inhibited OVA-induced eosinophil infiltration into the trachea of DO11.10 TCR transgenic mice at 24 h after OVA inhalation (PBS-fed 12.91 Ϯ 3.08 versus OVA-fed 1.63 Ϯ 0.62 eosinophils/mm, n ϭ 4 mice in each group, P Ͻ 0.001).
Discussion
In this study, we show that the induction of high-dose oral tolerance prevents T h 2 cell-mediated allergic inflammatory responses, i.e. eosinophil recruitment into the tissue and IgE antibody production. We found that oral administration of a protein antigen in high doses inhibited antigen-induced eosinophil recruitment into the airways and IgE antibody production in mice in an antigen-specific manner (Figs 1, 2  and 4) . The oral administration of antigen was also found to suppress both CD4 ϩ T cell recruitment into the airways and IL-5 levels in the BALF of the mice after antigen inhalation (Fig. 3) . We also found that in vitro antigen-induced production of IL-2, IFN-γ, IL-4 and IL-5 was decreased in spleen cells of antigen-fed mice ( Fig. 5 and 6 ), indicating the induction of both T h 1 and T h 2 cell tolerance in vivo. On the other hand, pretreatment with anti-TGF-β antibody at the time of immunization with antigen had no significant effect on the inhibition of antigen-induced eosinophil recruitment and IgE antibody production in antigen-fed mice (Fig. 7) . Finally, antigenspecific CD4 ϩ T cells were not deleted in TCR transgenic mice after antigen feeding by FACS analysis (Fig. 8) . Taken together, because it has been shown that antigen-induced eosinophil recruitment into the tissue and antigen-specific IgE production of sensitized mice are mediated by IL-5 (4) and IL-4 (19, 20) respectively, these results indicate that high-dose oral tolerance induces not only T h 1 but also T h 2 cell tolerance in vivo and thereby inhibits T h 2 cell-mediated allergic inflammation.
Our findings that high-dose oral tolerance inhibits T h 2 cellmediated allergic inflammation in the airways are consistent with a recent report by Garside et al. (21) that high-dose oral tolerance reduces the production of both T h 1 and T h 2 cell cytokines, and is accompanied by a reduction of both the IgG2a and IgG1 antibodies in mice. On the contrary, Melamed and Friedman (8) have shown that high-dose oral tolerance decreases in vitro IL-2 and IFN-γ production and in vivo IgG2a production, but does not decrease in vitro IL-4 production and in vivo IgG1 production. The difference in the effect of high-dose oral tolerance for the in vivo T h 2 responses between our study and their study is likely due to the differences in the numbers of antigen feeding, and the interval between antigen feeding and sensitization.
IFN-γ is a T h 1 cell-derived cytokine (5) that has been shown to inhibit T h 2 cell proliferation in vitro (22, 23) and antagonize T h 2-type responses in vivo (24) (25) (26) . Thus, it has been shown that IFN-γ prevents antigen-induced eosinophil recruitment into the tissue and IgE antibody production (16, 24) . However, immune deviation to a T h 1-type response is unlikely to explain the in vivo T h 2 cell tolerance of antigen-induced eosinophil recruitment and IgE antibody production by oral administration of antigen, as in vitro antigen-induced IL-2 and IFN-γ production of antigen-fed mice was found to be decreased (Fig. 5) . On the other hand, immune deviation to a T h 2-type response suppresses T h 1 cell-mediated autoimmune diseases. Scott et al. (27) demonstrated that in an experimental autoimmune diabetes using double-transgenic mice expressing both an antigen on the islet β cell and its corresponding TCR, the disease was suppressed by the generation of autoreactive T h 2 cells.
Because TGF-β has been shown to be an immunosuppressive cytokine that mediates oral tolerance of T h 1 cell-mediated autoimmune diseases (7), we studied the possible involvement of TGF-β in the induction of oral tolerance of T h 2 cellmediated allergic inflammatory responses. In addition, TGF-β has been shown to inhibit IL-4 and IL-5 production of T cells and induce the preferential development of T h 1 cells (28, 29) . TGF-β also inhibits the differentiation of B cells into Bε cells (30) . However, our finding of the failure of in vivo administration of anti-TGF-β antibody to reverse the inhibition of antigen-induced eosinophil recruitment and IgE antibody production in orally tolerant mice suggests that TGF-β is not significantly involved in the induction of oral tolerance of T h 2 cell-mediated allergic inflammation. We also found that in vitro antigen-induced production of active TGF-β was not significantly detected in spleen cells of antigen-fed, immunized or unimmunized mice, suggesting that TGF-β-producing T cells may not be significantly generated after oral administration of antigen in our study. In contrast, TGF-β has been shown to mediate oral tolerance of T h 1 cell-mediated experimental autoimmune encephalomyelitis (EAE) (7, 8, 10) . Miller et al. (8) showed that in vivo administration of anti-TGF-β antibody abrogated CD8 ϩ T cell-mediated oral tolerance in the rat model of EAE. Furthermore, the anti-TGF-β antibody treatment enhanced the severity of EAE in non-tolerant animals (8). Chen et al. (10) also reported that T h 2-type CD4 ϩ T cell clones derived from SJL mice that had been orally tolerized to major basic protein produced TGF-β together with IL-4 and IL-10, and suppressed EAE by the release of TGF-β.
Finally, we found that oral administration of antigen did not lead to deletion of antigen-specific CD4 ϩ T cells in vivo or down-regulation of the TCR expression of antigen-specific CD4 ϩ T cells. Therefore, it is unlikely that the in vivo T h 2 tolerance by antigen feeding results from down-regulation of TCR or clonal deletion, although it has been shown that mature peripheral CD4 ϩ and CD8 ϩ T cells to self antigens can be clonally eliminated after the encounter to the antigens (31, 32) .
In summary, we have shown that the induction of high-dose oral tolerance prevents T h 2 cell-mediated allergic inflammation, eosinophil recruitment into the tissue and IgE antibody production, and that the inhibition is mediated by T h 2 cell tolerance, but not by immune deviation to T h 1 cells, TGF-β or clonal deletion. These results suggest that oral tolerance could be applied to the therapy of T h 2 cell-mediated allergic diseases such as asthma.
